CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Tetracaine HCl 3% and Oxymetazoline HCl 0.05%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01304316
NCT01304316Phase 2Completed
CompareCT.gov

Cardiovascular Changes and Tetracaine Pharmacokinetics Following Intranasal Administration of Standard and High Doses of Kovacaine Mist (Tetracaine Hydrochloride With Oxymetazoline Hydrochloride) in Healthy Volunteers

St. Renatus, LLC·interventional·Posted Feb 25, 2011·Updated Aug 31, 2017

In Brief

A Phase 2 clinical trial evaluating Tetracaine HCl 3% and Oxymetazoline HCl 0.05% for Anesthesia. Completed, enrolled 12 participants across 1 site.

Detailed Summary

The purpose of this study is to determine the pharmacokinetics/pharmacodynamics and safety of a nasal spray containing the anesthetic drug tetracaine in combination with oxymetazoline

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnesthesia
CountriesUnited States
CollaboratorsGround Zero Pharmaceuticals, Rho, Inc.

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 25, 2011
Enrollment StartSep 1, 2010
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.4 years ago

Interventions

Tetracaine HCl 3% and Oxymetazoline HCl 0.05%drug

Tetracaine HCl 3% and Oxymetazoline HCl 0.05%